INVESTIGADORES
KAUFFMAN Marcelo Andres
artículos
Título:
Bioequivalence of Two Subcutaneous Pharmaceutical Products of Interferon Beta 1a
Autor/es:
DI GIROLAMO GUILLERMO; KAUFFMAN MARCELO; GONZALEZ ELISEO; PAPOUCHADO MARIANA; STERIN-PRYNC AIDA; DIEZ ROBERTO
Revista:
ARZNEIMITTEL FORSCHUNG DRUG RESEARCH
Editorial:
ECV-EDITIO CANTOR VERLAG MEDIZIN NATURWISSENSCHAFTEN
Referencias:
Año: 2008 vol. 58 p. 193 - 198
ISSN:
0004-4172
Resumen:
Blastoferon®, in the following referred to
as the test product, is a pharmaceutical
product of interferon beta 1a (CAS 220581-
49-7) currently marketed as a biosimilar
to the innovator interferon beta 1a product
(referred to as the reference product).
Pharmacokinetics and pharmacodynamics
assays are critically relevant to demonstrate
similarity between biopharmaceuticals.
The aims of the present study
were to investigate the bioavailability
(BA) of the test product (either absolute
or relative to the innovator product) and
to compare the extent of increase of
neopterin concentration following administration
of either product. Two studies
were performed: initially, an absolute
BA assay with i.v. and s.c. injection of test
product to 12 healthy subjects. Second, a
formal relative BA study with s.c. injections
of 88 μg of both products to 24
healthy volunteers. Blood samples for
pharmacokinetic and pharmacodynamic
profiling were drawn at different intervals
after injection. Interferon beta (IFNB)
concentrations were determined by ELISA.
In the absolute BA study, a single s.c. dose
of 44 μg of the test product resulted in a
median bioavailable fraction of 29 %, a
median Tmax of 4 h (46) and a Cmax of
3.69 (3.274.41) IU × ml-1.
In the relative BA study, values for the
test product were: median Tmax of 3 h
(218), Cmax of 5.39 (4.996.31) IU x ml-1,
AUC (0-72) of 142.86 (134.16190.15) IU × h
× ml-1 and AUC(0-infinity) of 190.95 (174.23
303.13) IU × h × ml-1. The corresponding
values for the innovator product were:
Tmax of 3 h (124), Cmax of 4.44 (4.125.40)
IU x ml-1, AUC(0-72) of 128.77 (121.18
170.92) IU × h × ml-1 and AUC(0-infinity) of
192.61 (183.04286.46) IU × h × ml-1. The
AUC(0-72) ratio was 111 % (CI 90 %: 106
116), the AUC(0-infinity) was 99 % (CI 90 %:
92107) and the Cmax ratio was 121 % (CI
90 %: 112131). IFNB1a increased neopterin
levels in both studies. Both products
induced side-effects commonly reported
for IFN with no serious adverse events.
This study presents pharmacokinetics parameters
of the test product and demonstrates
similar bioavailability of IFNB1a
for both pharmaceutical products.